1
|
Gao JH, Wang ZL, Liu HH, Wang LM and Huang
GH: Liposome encapsulated of temozolomide for the treatment of
glioma tumor: Preparation, characterization and evaluation. Drug
Discov Ther. 9:205–212. 2015. View Article : Google Scholar : PubMed/NCBI
|
2
|
Furnari FB, Fenton T, Bachoo RM, Mukasa A,
Stommel JM, Stegh A, Hahn WC, Liqon KL, Louis DN, Brennan C, et al:
Malignant astrocytic glioma: Genetics, biology, and paths to
treatment. Genes Dev. 21:2683–2710. 2007. View Article : Google Scholar : PubMed/NCBI
|
3
|
Gilbert MR, Wang M, Aldape KD, Stupp R,
Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT,
et al: Dose-dense temozolomide for newly diagnosed glioblastoma: A
randomized phase III clinical trial. J Clin. Oncol. 31:4085–4091.
2013.
|
4
|
Lan YL, Wang X, Xing JS, Lou JC, Ma XC and
Zhang B: The potential roles of dopamine in malignant glioma. Acta
Neurol Belg. 117:613–621. 2017. View Article : Google Scholar : PubMed/NCBI
|
5
|
McKellar QA and Benchaoui HA: Avermectins
and milbemycins. J Vet Pharmacol Ther. 19:331–351. 1996. View Article : Google Scholar : PubMed/NCBI
|
6
|
Cotreau MM, Warren S, Ryan JL,
Fleckenstein L, Vanapalli SR, Brown KR, Rock D, Chen CY and
Schwertschlag US: The antiparasitic moxidectin: Safety,
tolerability, and pharmacokinetics in humans. J Clin Pharmacol.
43:1108–1115. 2003. View Article : Google Scholar : PubMed/NCBI
|
7
|
Prichard R, Ménez C and Lespine A:
Moxidectin and the avermectins: Consanguinity but not identity. Int
J Parasitol Drugs and Drug Resist. 14:134–153. 2012. View Article : Google Scholar
|
8
|
Perez M, Blazquez AG, Real R, Mendoza G,
Prieto JG, Merino G and Alvarez AI: In vitro and in vivo
interaction of moxidectin with BCRP/ABCG2. Chem Biol Interact.
180:106–112. 2009. View Article : Google Scholar : PubMed/NCBI
|
9
|
Zulalian J, Stout SJ, Cunha AR, Garces T
and Miller P: Absorption, tissue distribution, metabolism, and
excretion of moxidectin in cattle. J Agric Food Chem. 42:381–387.
1994. View Article : Google Scholar
|
10
|
Afzal J, Stout SJ, da Cunha AR and Miller
P: Moxidectin: Absorption, tissue distribution, excretion, and
biotransformation of 14C-labeled moxidectin in sheep. J Agric Food
Chem. 42:1767–1773. 1994. View Article : Google Scholar
|
11
|
Afzal J, Burke AB, Batten PL, DeLay RL and
Miller P: Moxidectin: Metabolic fate and blood pharmacokinetics of
14C-labeled moxidectin in horses. J Agric Food Chem. 45:3627–3633.
1997. View Article : Google Scholar
|
12
|
Traversa D, Di Cesare A, Milillo P, Lohr
B, Iorio R, Pampurini F, Schaper R, Paoletti B and Heine J:
Efficacy and safety of imidacloprid 10%/moxidectin 1% spot-on
formulation in the treatment of feline aelurostrongylosis.
Parasitol Res. 105 Suppl 1:S55–S62. 2009. View Article : Google Scholar : PubMed/NCBI
|
13
|
Verma M, Pathak M, Shahab M, Singh K,
Mitra K and Misra-Bhattacharya S: Moxidectin causes adult worm
mortality of human lymphatic filarial parasite Brugia malayi in
rodent models. Folia Parasitol. 61:561–570. 2014. View Article : Google Scholar : PubMed/NCBI
|
14
|
Gao A, Wang X, Xiang W, Liang H, Gao J and
Yan Y: Reversal of P-glycoprotein-mediated multidrug resistance in
vitro by doramectin and nemadectin. J Pharm Pharmacol. 62:393–399.
2010. View Article : Google Scholar : PubMed/NCBI
|
15
|
Korystov YN, Ermakova NV, Sterlina LN,
Levitman MK, Shaposhnikova VV, Mosin VA, Drinyaev VA, Kruglyak EB,
Novik TS and Sterlina TS: Avermectins inhibit multidrug resistance
of tumor cells. Eur J Pharmacol. 493:57–64. 2004. View Article : Google Scholar : PubMed/NCBI
|
16
|
Mani T, Bourguinat C, Keller K, Asraf S,
Blagburn B and Prichard RK: Interaction of macrocyclic lactones
with a Dirofilaria immitis P-glycoprotein. Int J Parasitol.
46:631–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
17
|
Dou Q, Chen HN, Wang K, Yuan K, Lei Y, Li
K, Lan J, Chen Y, Huang Z, Xie N, et al: Ivermectin induces
cytostatic autophagy by blocking the PAK1/Akt axis in breast
cancer. Cancer Res. 76:4457–4469. 2016. View Article : Google Scholar : PubMed/NCBI
|
18
|
Liu YY, Fang SS, Sun QS and Liu B:
Anthelmintic drug ivermectin inhibits angiogenesis, growth and
survival of glioblastoma through inducing mitochondrial dysfunction
and oxidative stress. Biochem Biophys Res Commun. 480:415–421.
2016. View Article : Google Scholar : PubMed/NCBI
|
19
|
Farkas R, Hell E and Palfi T: The efficacy
of four anthelmintics against small strongyles in a stud farm in
Hungary. Magyar Allatorvosok Lapja. 128:291–297. 2006.
|
20
|
Lespine A, Martin S, Dupuy J, Roulet A,
Pineau T, Orlowski S and Alvinerie M: Interaction of macrocyclic
lactones with P-glycoprotein: Structure-affinity relationship. Eur
J Pharm Sci. 30:84–94. 2007. View Article : Google Scholar : PubMed/NCBI
|
21
|
Mounsey KE, Bernigaud C, Chosidow O and
McCarthy JS: Prospects for moxidectin as a new oral treatment for
human scabies. PLos Negl Trop Dis. 10:e00043892016. View Article : Google Scholar : PubMed/NCBI
|
22
|
Fazzio LE, Streitenberger N, Galvan WR,
Sánchez RO, Gimeno EJ and Sanabria RE: Efficacy and productive
performance of moxidectin in feedlot calves infected with nematodes
resistant to ivermectin. Vet Parasitol. 223:26–29. 2016. View Article : Google Scholar : PubMed/NCBI
|
23
|
Lloberas M, Alvarez L, Entrocasso C,
Virkel G, Ballent M, Mate L, Lanusse C and Lifschitz A: Comparative
tissue pharmacokinetics and efficacy of moxidectin, abamectin and
ivermectin in lambs infected with resistant nematodes: Impact of
drug treatments on parasite P-glycoprotein expression. Int. J
Parasitol Drugs Drug Resist. 3:20–27. 2013. View Article : Google Scholar
|
24
|
Jiang Z, Chai J, Chuang HH, Li S, Wang T,
Cheng Y, Chen W and Zhou D: Artesunate induces G0/G1 cell cycle
arrest and iron-mediated mitochondrial apoptosis in A431 human
epidermoid carcinoma cells. Anticancer Drugs. 23:606–613. 2012.
View Article : Google Scholar : PubMed/NCBI
|
25
|
Wu X, Wu MY, Jiang M, Zhi QM, Bian J, Xu
MD, Gong FR, Hou J, Tao M, Shou LM, et al: TNF-α sensitizes
chemotherapy and radiotherapy against breast cancer cells. Cancer
Cell Int. 17:132017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Guichet PO, Guelfi S, Ripoll C, Teigell M,
Sabourin JC, Bauchet L, Rigau V, Rothhut B and Hugnot JP:
Asymmetric distribution of GFAP in glioma multipotent Cells. PLos
One. 11:e01512742016. View Article : Google Scholar : PubMed/NCBI
|
27
|
Zhou XM, Sun R, Luo DH, Sun J, Zhang MY,
Wang MH, Yang Y, Wang HY and Mai SJ: Upregulated TRIM29 promotes
proliferation and metastasis of nasopharyngeal carcinoma via
PTEN/AKT/mTOR signal pathway. Oncotarget. 7:13634–13650.
2016.PubMed/NCBI
|
28
|
Janko C and Geyer J: Moxidectin has a
lower neurotoxic potential but comparable brain penetration in
P-glycoprotein-deficient CF-1 mice compared to ivermectin. J Vet
Pharmacol Ther. 36:275–284. 2013. View Article : Google Scholar : PubMed/NCBI
|
29
|
Xiang WS, Gao AL, Liang HS, Li CY, Gao JG,
Wang Q, Shuang B, Zhang J, Yan YJ and Wang XJ: Reversal of
P-glycoprotein-mediated multidrug resistance in vitro by milbemycin
compounds in adriamycin-resistant human breast carcinoma
(MCF-7/adr) cells. Toxicol In Vitro. 24:1474–1481. 2010. View Article : Google Scholar : PubMed/NCBI
|
30
|
Mattern J and Volm M: Imbalance of cell
proliferation and apoptosis during progression of lung carcinomas.
Anticancer Res. 24:4243–4246. 2004.PubMed/NCBI
|
31
|
Wong RS: Apoptosis in cancer: From
pathogenesis to treatment. J Exp Clin Cancer Res. 30:872011.
View Article : Google Scholar : PubMed/NCBI
|
32
|
Danial NN: BCL-2 family proteins: Critical
checkpoints of apoptotic cell death. Clin Cancer Res. 13:7254–7263.
2007. View Article : Google Scholar : PubMed/NCBI
|
33
|
Xiong S, Mu T, Wang G and Jiang X:
Mitochondria-mediated apoptosis in mammals. Protein Cell.
5:737–749. 2014. View Article : Google Scholar : PubMed/NCBI
|
34
|
Ekert PG, Read SH, Silke J, Marsden VS,
Kaufmann H, Hawkins H, Hawkins CJ, Gerl R, Kumar S and Vaux DL:
Apaf-1 and caspase-9 accelerate apoptosis, but do not determine
whether factor-deprived or drug-treated cells die. J Cell Biol.
165:835–842. 2004. View Article : Google Scholar : PubMed/NCBI
|
35
|
Youle RJ and Strasser A: The BCL-2 protein
family: Opposing activities that mediate cell death. Nat Rev Mol
Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
|
36
|
Kang MH and Reynolds CP: Bcl-2 inhibitors:
Targeting mitochondrial apoptotic pathways in cancer therapy. Clin
Cancer Res. 15:1126–1132. 2009. View Article : Google Scholar : PubMed/NCBI
|
37
|
Liang BX, Liu ZY, Cao YN, Zhu C, Zuo Y,
Huang L, Wen G, Shang N, Chen Y, Yue X, et al: MC37, a new
mono-carbonyl curcumin analog, induces G2/M cell cycle arrest and
mitochondria-mediated apoptosis in human colorectal cancer cells.
Eur J Pharmacol. 796:139–148. 2017. View Article : Google Scholar : PubMed/NCBI
|
38
|
Gogvadze V, Orrenius S and Zhivotovsky B:
Multiple pathways of cytochrome c release from mitochondria in
apoptosis. Biochim Biophys Acta. 1757:639–647. 2006. View Article : Google Scholar : PubMed/NCBI
|
39
|
Singh PK and Kumar A: Mitochondria
mediates caspase-dependent and independent retinal cell death in
Staphylococcus aureus endophthalmitis. Cell Death Discov.
2:160342016. View Article : Google Scholar : PubMed/NCBI
|
40
|
Lee JH, Jung JY, Jeong YJ, Park JH, Yang
KH, Yang KH, Choi NK, Kim SH and Kim WJ: Involvement of both
mitochondrial- and death receptor-dependent apoptotic pathways
regulated by Bcl-2 family in sodium fluoride-induced apoptosis of
the human gingival fibroblasts. Toxicology. 243:340–347. 2008.
View Article : Google Scholar : PubMed/NCBI
|
41
|
Wan D, Jiang C, Hua X, Wang T and Chai M:
Cell cycle arrest and apoptosis induced by aspidin PB through the
p53/p21 and mitochondria-dependent pathways in human osteosarcoma
cells. Anticancer Drugs. 26:931–941. 2015. View Article : Google Scholar : PubMed/NCBI
|
42
|
McGinnis GR and Young ME: Circadian
regulation of metabolic homeostasis: Causes and consequences. Nat
Sci Sleep. 8:163–180. 2016.PubMed/NCBI
|
43
|
Lin CJ, Chang YA, Lin YL, Liu SH, Chang CK
and Chen RM: Preclinical effects of honokiol on treating
glioblastoma multiforme via G1 phase arrest and cell apoptosis.
Phytomedicine. 23:517–527. 2016. View Article : Google Scholar : PubMed/NCBI
|
44
|
Cocquyt CM, Van Amstel S, Cox S, Rohrbach
B and Martín-Jiménez T: Pharmacokinetics of moxidectin in alpacas
following administration of an oral or subcutaneous formulation.
Res Vet Sci. 105:160–164. 2016. View Article : Google Scholar : PubMed/NCBI
|
45
|
Lespine A, Chanoit G, Bousquet-Melou A,
Lallemand E, Bassissi FM, Alvinerie M and Toutain PL: Contribution
of lymphatic transport to the systemic exposure of orally
administered moxidectin in conscious lymph duct-cannulated dogs.
Eur J Pharm Sci. 27:37–43. 2006. View Article : Google Scholar : PubMed/NCBI
|
46
|
Dupuy J, Larrieu G, Sutra JF, Eeckhoutte C
and Alvinerie M: Influence of verapamil on the efflux and
metabolism of 14C moxidectin in cultured rat hepatocytes. J Vet
Pharmacol Ther. 24:171–177. 2001. View Article : Google Scholar : PubMed/NCBI
|